Valbenazine + Placebo oral capsule

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome

Trial Timeline

Oct 5, 2017 → Nov 16, 2018

NCT ID

NCT03325010

About Valbenazine + Placebo oral capsule

Valbenazine + Placebo oral capsule is a phase 2 stage product being developed by Neurocrine Biosciences for Tourette Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03325010. Target conditions include Tourette Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03891862	Approved	Completed	Mar 18, 2019	Jan 30, 2020	Tardive Dyskinesia (TD)
NCT03698331	Approved	Completed	Sep 14, 2018	Apr 3, 2019	Tardive Dyskinesia (TD)
NCT03530293	Phase 2	Terminated	Apr 17, 2018	Jul 16, 2019	Tourette Syndrome
NCT03325010	Phase 2	Completed	Oct 5, 2017	Nov 16, 2018	Tourette Syndrome

Competing Products

12 competing products in Tourette Syndrome

See all competitors

Product	Company	Stage	Hype Score
AZD5213 and placebo	AstraZeneca	Phase 2	35
PF-03654746 + Placebo + Placebo + PF-03654746	Pfizer	Phase 2	27
Aripiprazole	Bristol Myers Squibb	Pre-clinical	18
NBI-98854	Neurocrine Biosciences	Phase 2	24
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	24
Valbenazine	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 1	26
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Abobotulinum toxin A	Ipsen	Pre-clinical	19
Tetrabenazine MR + Placebo	Bausch Health	Phase 2	21